Guggenheim analyst Michael Schmidt raised the firm’s price target on Tango Therapeutics (TNGX) to $12 from $10 and keeps a Buy rating on the shares after the company disclosed Phase 1/2 vopimetostat data in solid tumor patients. The firm is updating its model and estimates and increasing its odds of success assumption for vopimetostat following the data.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNGX: